← Back to all trials
Enrolling By Invitation
NCT07888595
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Conditions: Aging
Sex: All
Ages: 50 Years – 100 Years
Healthy volunteers: Yes
Phase: EARLY_PHASE1
Enrollment: 48
Sponsor: Frontiers in Bioscience Research Institute and Aging
Location: Frontiers in Bioscience Research Institute in Aging and Cancer Irvine California
Summary
This study tests whether certain medicines and a skin treatment can slow down or partly reverse the body's aging process.
As people age, the activity of their genes changes in predictable ways. Researchers can now measure a person's "biological age" from these gene-activity patterns in skin and blood. This study uses that measurement to see whether treatment can lower a person's biological age compared with their own starting point.
Adults in the study take geroprotective ("age-protecting") agents by mouth or by injection. A separate skin serum containing small anti-aging peptides is applied to certain areas of skin, and those treated areas are compared with untreated areas on the same person.
Skin and blood samples are taken at set times to measure biological age and markers of cell aging before, during, and after treatment. The main goal is to find out whether treatment lowers measured biological age in skin and blood. The study also looks at whether the treatments are safe and well tolerated.
Eligibility Criteria
Inclusion Criteria:
* Men and women aged 50 years or older
* Healthy, free of chronic or age-related disease
* Not taking medication for any disease
* Willing to provide blood, skin (biopsy or exfoliated cells), plucked hair, and/or saliva samples at scheduled timepoints
* Able to understand and provide written informed consent
Exclusion Criteria:
* Age under 50 years
* Pregnancy or breastfeeding
* Unable to provide informed consent
* Bedridden, comatose, or not coherent
* Any chronic, acute, or age-related disease
* Current use of any medication for a disease, including any agent with a clinically significant interaction with a study agent
* Known hypersensitivity, allergy, or prior reaction/side effect to any study agent (metformin, chloroquine, ivermectin, supplement components, or topical peptides)
* Active malignancy or systemic immunosuppression
* Significant renal, hepatic, cardiac, or retinal disease
* Smokers
* Alcohol use disorder
* Prisoners
Source: ClinicalTrials.gov (NCT07888595). StuddyBuddy aggregates publicly available trial information.